Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2019-11-19 Regulatory Filings
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
CS PHN - Junia Pharma lancia Blefarene Baby 19_11_2019
Regulatory Filings Classification · 1% confidence The document is a formal communication identified by the header "Informazione Regolamentata n. 20106-30-2019" and dated November 19, 2019. The subject is "CS PHN - Junia Pharma lancia Blefarene" (Junia Pharma launches Blefarene). The content details the launch of a new product, Blefarene Baby, by a subsidiary, including quotes from management about the product and the company's development plan. This structure—a formal announcement of a business event (product launch) released via regulatory channels (indicated by the header format and the use of 'REGEM' as the type)—is characteristic of a general regulatory announcement that doesn't fit into specific financial reporting categories like 10-K, ER, or IR. Since it is a specific business update released through regulatory means and doesn't fit other specific codes (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document length (6262 chars) is substantial enough to be the primary announcement itself, not just a brief notice of publication.
2019-11-19 Italian
CS - PHN concessione nuovo brevetto 12_11_2019
Regulatory Filings Classification · 1% confidence The document is an official communication from Pharmanutra S.p.A. dated November 12, 2019, identified as 'Informazione Regolamentata' (Regulated Information) with the object 'CS - PHN concessione nuovo brevetto' (Press Release - PHN grant of new patent). The content details the granting of a new patent related to cardiovascular treatment. This is a specific corporate announcement regarding an intellectual property development, not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a general regulatory filing (RNS). Since it announces a specific corporate event (patent grant) that impacts the company's future development and assets, it is best classified as a general corporate announcement. Given the provided definitions, 'Regulatory Filings' (RNS) is the most appropriate fallback for specific, non-financial, non-management, non-dividend, non-shareholder meeting announcements that are mandatory disclosures. However, the content is highly specific to R&D/IP, which doesn't fit perfectly into the other categories. Since it is a specific, material corporate event disclosure, and not a standard financial report or management change, RNS serves as the best fit among the available options for a specific, non-standard announcement.
2019-11-12 Italian
CS Pharmanutra brevetto ferro USA
Investor Presentation Classification · 1% confidence The document is an official communication (Informazione Regolamentata) from Pharmanutra S.p.A. dated November 5, 2019. The subject (Oggetto) is 'CS Pharmanutra brevetto ferro USA' (Pharmanutra press release iron patent USA). The content details the granting of a patent for 'Ferro Solido' in the USA, which is a matter of intellectual property and strategic corporate development. This type of announcement, focusing on a specific corporate event (patent grant) rather than routine financial results (ER, IR) or governance documents (DEF 14A, CGR), fits best under the category of general corporate news or regulatory disclosure that isn't covered by more specific codes. Since the core topic is the acquisition of intellectual property rights (a patent), and it is presented as a formal press release/communication, it relates closely to the company's assets and strategic positioning. While 'LTR' (Legal Proceedings Report) is for lawsuits, this is about securing rights. Given the options, this is a specific corporate announcement. It is not a standard financial report (10-K, IR), nor a management/board change (MANG). It is a disclosure about a key asset. Since there isn't a specific 'Intellectual Property Announcement' code, and it is a formal regulatory disclosure ('Informazione Regolamentata'), the most appropriate general category for significant, non-financial, non-governance specific news that must be disclosed is 'Regulatory Filings' (RNS), as it is a formal, time-stamped regulatory release that doesn't fit the other specific categories like DIV, CAP, or MANG. However, the content is fundamentally about intellectual property rights, which is a key component of corporate value. If we strictly follow the definitions, 'RNS' is the fallback. Let's re-evaluate if any other code fits better. It is not a Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP). It is a disclosure of a strategic asset acquisition (patent). Given the options, RNS (Regulatory Filings/Miscellaneous) is the safest classification for a formal, non-standard announcement.
2019-11-05 Italian
CS Pharmanutra Semestrale 2019
Earnings Release Classification · 1% confidence The document is a press release from PharmaNutra S.p.A. announcing its consolidated half-year financial results for the period ending June 30, 2019. It contains key financial highlights, management commentary, and summary financial tables (balance sheet and income statement). While it includes summary financial data, it is structured as a corporate communication (press release) rather than the full, formal interim financial report itself, which is referenced as being available separately. Therefore, it is classified as an Earnings Release. H1 2019
2019-09-16 Italian
CS Pharmanutra - Accordo WERT Philippines 090919
Regulatory Filings Classification · 1% confidence The document is a formal communication identified by the header 'Informazione Regolamentata' (Regulated Information) and a specific reception date (10 Settembre 2019). The subject line is 'CS Pharmanutra - Accordo WERT Philippines 090919', and the content details the signing of a new distribution agreement for their Sideral® line in the Philippines. This type of announcement, which communicates a significant business development (a new partnership/agreement) to the market, is typically classified as a general regulatory announcement or press release. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific transaction report (like DIRS or POS), the most appropriate general category for a material business update that is not otherwise specified is 'Regulatory Filings' (RNS), which serves as a broad category for material, non-standardized disclosures. The document length (6897 chars) is substantial enough to be the primary disclosure, not just an announcement of an attachment (RPA).
2019-09-10 Italian
CS Pharmanutra Taiwan 280819
Regulatory Filings Classification · 1% confidence The document is a press release from PharmaNutra S.p.A. dated August 28, 2019, announcing a new distribution agreement for its SiderAL® line in Taiwan. The header indicates it is 'Informazione Regolamentata' (Regulated Information) and the content is a corporate announcement regarding business development (international expansion/partnership). This type of announcement, which details strategic business events rather than periodic financial results (like 10-K or IR) or specific insider transactions (DIRS), typically falls under general regulatory announcements or press releases. Since it is not a formal financial report, a dividend notice, or a specific management change, and it is a formal communication to the market, it best fits the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official corporate news releases that don't fit elsewhere. It is not a Call Transcript (CT), Earnings Release (ER), or a specific financial filing like 10-K or IR.
2019-08-28 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.